Estrella Immunopharma Inc.

Estrella Immunopharma, Inc. is a preclinical-stage biopharmaceutical company based in Emeryville, California, that develops T-cell therapies for blood cancers and solid tumors in the United States. Its lead product candidates include EB103, in preclinical trials for diffuse large B-cell lymphoma, and EB104, for diffuse large B-cell lymphoma and acute lymphocytic leukemia. The company has a collaborative partnership with Imugene Limited to develop solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103.